IL-10 Treatment Is Associated with Prohibitin Expression in the Crohn’s Disease Intestinal Fibrosis Mouse Model

Table 2

Gene expression of prohibitin, Nrf2, collagen I, 𝛼-SMA, and TGF-β1 (𝑥±𝑠,%).

Group-week	n	Prohibitin	TGF-β1	Nrf2	Collagen I	α-SMA
12 wk
Control	6	4.60 ± 0.72	0.32 ± 0.15	1.58 ± 1.01	0.45 ± 0.24	0.36 ± 0.43
IL-10KO	6	0.74 ± 0.15^a	1.12 ± 0.22^a	0.92 ± 0.42^a	1.13 ± 0.21^a	0.98 ± 0.48^a
14 wk
Control	6	5.10 ± 1.32	0.28 ± 0.16	1.21 ± 0.64	0.40 ± 0.33	0.47 ± 0.13
IL-10KO	6	0.53 ± 0.22^a	1.48 ± 0.24^a	0.46 ± 0.27^a	1.68 ± 0.51^a	1.58 ± 0.36^a
IL-10 treated	6	1.85 ± 0.41^ab	0.62 ± 0.12^ab	1.09 ± 0.49^ab	1.10 ± 0.49^ab	1.18 ± 0.11^ab
16 wk
Control	6	4.94 ± 1.05	0.31 ± 0.20	1.62 ± 0.85	0.42 ± 0.24	0.42 ± 0.33
IL-10KO	6	0.42 ± 0.03^a	1.91 ± 0.55^a	0.32 ± 0.15^a	1.88 ± 0.27^a	1.91 ± 0.95^a
IL-10 treated	6	2.51 ± 0.28^b	0.33 ± 0.10^b	2.13 ± 1.04^b	0.76 ± 0.25^ab	0.81 ± 0.50^ab

^a𝑃<0.05, versus control group; ^b𝑃<0.05, versus IL-10KO mice group.